Efficacy and Safety of Bevacizumab Combined With Double Doses of Icotinib in Advanced Non-squamous Non-small Cell Lung Cancer With EGFR Exon 21 L858R Mutation: a Prospective, Single-arm, Phase 2 Clinical Trial
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Bevacizumab (Primary) ; Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jul 2025 Status changed from recruiting to completed.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 13 Jan 2023 According to ClinicalTrials.gov record, protocol has been amended to decrease patient number from 284 to 35, Phase has been changed from Phase III to Phase II. number of arms are changed as well..